Pharmacological Approach for Obesity

Kusti, Mohannad; Olgers, Forrest; Akkary, Ehab

doi:10.2174/978160805163211101010067

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Canagliflozin (CANA), a sodium-glucose cotransporter 2 (SGLT2) inhibitor for the treatment of adults with type 2 diabetes, lowers the renal threshold for glucose reabsorption (RTG), thereby increasing urinary glucose excretion (UGE) and resulting in amild osmotic diuresis and a net caloric loss (32,33). Phentermine (PHEN), a sympathomimetic amine anorectic that stimulates satiety centers in the brain via upregulation of dopamine, noradrenaline, and serotonin, is indicated for short-term weight management (34).…”

Section: Coadministration Of Canagliflozin and Phenterminementioning

confidence: 99%

Safety of Anti-Obesity Agents in Adults Narrative Review

Hussain Al-Herz,

Abdo Al-Dubai

2023

IJAR

View full text Add to dashboard Cite

Background: Weight management medications are appropriate treatment options for individuals who are overweight or obese and have been unable to achieve weight loss with lifestyle intervention alone. In this narrative review, we aimed to review the adverse effects and safety profile of anti-obesity agents in overweight and obese patients. Methods: PubMed database was were systematically searched for relevant studies published between January 2012 and July 2022 of randomized controlled trials phase II or III of anti-obesity agents, for adult 18 years old with overweight or obesity without diabetes mellitus or secondary causes of obesity.Studies that met eligibility criteria were extracted and reviewed. 48 studies were screened for eligibility, among them, 18 studies fulfill inclusion criteria and involved in the narrative review.

show abstract

Section: Coadministration Of Canagliflozin and Phenterminementioning

confidence: 99%